Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Simon Mendelsohn (cohort 2015-16) co-authored this article.

We evaluated longitudinal kinetics of an 11-gene blood transcriptomic tuberculosis (TB) signature, RISK11, and effects of TB preventative therapy (TPT) and respiratory organisms on RISK11 signature score, in HIV-uninfected and HIV-infected individuals. Methods RISK11 was measured in a longitudinal study of RISK11-guided TPT in HIV-uninfected adults, a cross-sectional respiratory organisms cohort or a longitudinal study in people living with HIV (PLHIV). HIV-uninfected RISK11+ participants were randomised to TPT or no TPT; RISK11- participants received no TPT. PLHIV received standard-of-care ART and TPT. In the cross-sectional respiratory organisms cohort, viruses and bacteria in nasopharyngeal and oropharyngeal swabs were quantified by RT-qPCR. Measurements and Main Results RISK11+ status was transient in most of the 128 HIV-negative participants with longitudinal samples; >70% of RISK11+ participants reverted to RISK11- by 3 months, irrespective of TPT. By comparison, reversion from a RISK11-positive state was less common in 645 PLHIV (42.1%). Non-HIV viral and non-tuberculous bacterial organisms were detected in 7.2% and 38.9% of the 1,000 respiratory organisms cohort participants, respectively, and among those investigated for TB, 3.8% had prevalent disease. Median RISK11 scores (%) were higher in participants with viral organisms alone (46.7%), viral and bacterial organisms (42.8%), or prevalent TB (85.7%), than those with bacterial organisms other than TB (13.4%), or no organisms (14.2%). RISK11 could not discriminate between prevalent TB and viral organisms. Conclusions Positive RISK11 signature status is often transient, possibly due to intercurrent viral infection, highlighting potentially important challenges for implementation of these biomarkers as new tools for TB control. This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

 

Visit the American Journal of Respiratory and Critical Care Medicine to read the full article.

Similar stories

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Sandra Adele (cohort 2019-2020) co-authored this paper assessing the benefits of interval extension between BNT162b2 mRNA vaccine doses.

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Simon Mendelsohn (cohort 2015-16) co-authored this systematic review protocol on the current triage and predictive tools and how host tuberculosis transcriptomic biomarkers may be more effective for a correct diagnosis.

Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20–22 April 2021

Simon Mendelsohn (cohort 2015-16) co-authored this article on the Global Forum on Tuberculosis (TB) Vaccines and how this year's event focussed on opportunities and challenges for TB vaccine R&D during a pandemic.

Delays in presentation of intussusception and development of gangrene in Zimbabwe

Student Dennis Mazingi (cohort 2020-2021) co-authored this paper focused on the importance of a prompt diagnosis and treatment of intussusception in Zimbabwe. Their findings highlight the need to improve early diagnosis of intussusception and prompt referral of patients for treatment.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Sandra Adele (cohort 2019-2020) co-authored this paper on the efficacy of the Oxford Astra-Zeneca vaccine for the 40 million people globally living with HIV. This study aimed to assess the vaccine’s ability to stimulate an immune response on those who have their immunity compromised.

Alumna Parinda Wattanasri (cohort 2019-2020) talks about vaccine passports in Thailand Today

Alumna Parinda Wattanasri (cohort 2019-2020) was interviewed by Thailand Today on vaccine passports. and how they may become a sustainable plan to reopening Thailand.